News & Events

Upcoming Events

There are currently no events to display.

News Releases

Date Title and Summary
Toggle Summary Juno Therapeutics Names Cindy Elkins as Chief Information Officer
SEATTLE --(BUSINESS WIRE)--Jan. 5, 2018-- Juno Therapeutics , Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the appointment of Cindy Elkins as Chief Information Officer (CIO).
Toggle Summary Juno Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
SEATTLE --(BUSINESS WIRE)--Jan. 3, 2018-- Juno Therapeutics, Inc. (NASDAQ:JUNO) today announced that it will webcast its presentation at the 36 th Annual J.P. Morgan Healthcare Conference at 4:00 p.m. PT on Tuesday, January 9, 2018 . The presentation will feature a business overview and update by
Toggle Summary Juno Therapeutics Highlights Data and Presentations Supporting Best-in-Class Strategy for JCAR017 at ASH
—Updated JCAR017 (liso-cel) data in core group at dose level 2 showed 74% (14/19) ORR and 68% (13/19) CR rate at 3 months, with 50% (7/14) CR at 6 months— —JCAR017 data continue to support better responses at dose level 2 without increased toxicity observed for CRS and NT compared to dose level 1
Toggle Summary Juno Therapeutics and Celgene Corporation Release Additional Data from TRANSCEND Trial of JCAR017 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
—74% (14/19) ORR and 68% (13/19) CR rate at 3 months and 50% (7/14) CR at 6 months in core group at dose level 2— —Across doses, 80% (16/20) of core group patients in CR at month 3 remain in response at month 6; 92% (11/12) of core group patients in response at 6 months remain in response as of
Toggle Summary Juno Therapeutics Highlights Key Translational Insights with JCAR017 in Patients with DLBCL
— Patient factors may impact safety and efficacy outcomes— —JCAR017 cells infiltrated tumors, more infiltration trended with better response— —At disease progression, tumors tended to express CD19 and lack CAR T cells— SEATTLE --(BUSINESS WIRE)--Dec. 9, 2017-- Juno Therapeutics ,
Toggle Summary Juno Therapeutics Signs Licensing Agreements with Lilly, OncoTracker, and Fred Hutchinson Cancer Research Center to Advance Its BCMA-Directed Engineered T Cell Program in Multiple Myeloma with Gamma Secretase Inhibition
SEATTLE --(BUSINESS WIRE)--Dec. 6, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced three license agreements to advance its program in multiple myeloma using gamma secretase
Toggle Summary Juno Therapeutics Appoints Ann L. Lee as Executive Vice President of Technical Operations and Patrick Y. Yang as Executive Vice President, Senior Advisor to the CEO
Experienced and accomplished executive additions with proven track records in scaling manufacturing, process development, and CMC portfolio management SEATTLE --(BUSINESS WIRE)--Nov. 27, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular
Toggle Summary Juno Therapeutics to Present at November 2017 Investor Conferences
SEATTLE --(BUSINESS WIRE)--Nov. 6, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentations at two investor conferences in November. The presentations will feature a business overview and update by Steve Harr , Juno’s Chief Financial Officer and Head of
Toggle Summary Juno Therapeutics Reports Third Quarter 2017 Financial Results
- TRANSCEND pivotal trial ongoing using dose level 2 - - Promising data with JCAR017 in DLBCL at dose level 2: 80% (12/15) ORR and 73% (11/15) CR rate at 3 months in core group - - 1% (1/69) severe CRS and 14% (10/69) severe NT rates in full group: safety profile appears similar across doses as
Toggle Summary Juno Therapeutics to Highlight New Advances in CD19- and BCMA-Targeted CAR T Therapy at ASH
- 15 abstracts to be presented at upcoming ASH Conference - - Promising data with JCAR017 in DLBCL at dose level 2: 80% (12/15) ORR and 73% (11/15) CR rate at 3 months in core group - - Additional presentations on JCAR017 outpatient administration, JCAR017 translational insights, and multiple